Navigation Links
Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
Date:7/29/2008

~ Initiates IDX184 Phase I Clinical Study and Advances HCV Protease Inhibitor and Non-Nucleoside Polymerase Inhibitor Clinical Candidates into

IND-Enabling Preclinical Studies ~

CAMBRIDGE, Mass., July 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today announced that it has initiated a first-in-man study of IDX184 under a United States investigational new drug (IND) application. IDX184 is a once-daily, oral nucleotide prodrug polymerase inhibitor for the treatment of chronic hepatitis C. Today, Idenix also announced that is has selected a lead clinical candidate (IDX375) from its HCV non-nucleoside polymerase inhibitor discovery program and has advanced IDX375 into IND-enabling pharmacokinetic and toxicology studies. Idenix has also advanced two protease inhibitor drug candidates (IDX136 and IDX316) into IND-enabling pharmacokinetic and toxicology studies.

"We are pleased with the progress we have made in our hepatitis C discovery program in the past few months," said Jean-Pierre Sommadossi, Ph.D., chief executive officer of Idenix. "With IDX184 entering human testing and clinical candidates undergoing late-stage preclinical testing from our HCV non-nucleoside and protease inhibitor programs, we are progressing toward our ultimate goal of developing a proprietary combination of direct-acting antivirals for the treatment of hepatitis C."

IDX184 Nucleotide Prodrug Polymerase Inhibitor

IDX184 is a once-daily, oral nucleotide prodrug candidate based on Idenix's proprietary liver-targeting technology that has demonstrated HCV
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
4. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
6. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
7. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
8. BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial
9. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
10. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
11. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... CryoLife, Inc. (NYSE: CRY), a leading medical ... vascular surgery, announced today that its Board of Directors ... quarter 2014 of $0.03 per share of common stock ... will be paid on September 19, 2014 to all ... The ex-dividend date for the quarterly dividend is September ...
(Date:7/30/2014)... 30, 2014 PuraMed BioScience ® , ... over-the-counter (OTC) medicinal and healthcare products, announced today ... name along with the name,s red and yellow ... trademarked name MigraPure ®  going forward. The ... homeopathic, natural migraine pain reliever will be reintroduced ...
(Date:7/30/2014)... 30, 2014  El Camino Hospital, a leader in ... utilizing the Leaf Patient Monitoring system to help prevent ... of patients susceptible to bed sores. The ... study of the system, which showed dramatic improvement in ... regularly is the one of the most effect ways ...
Breaking Medicine Technology:CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 2CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 3PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3
(Date:7/31/2014)... Parsippany, NJ (PRWEB) July 31, 2014 A ... millions of people survive cancer and resume normal lives. This ... American Cancer Society, will affect one in seven American men ... are, has a five-year survival rate of nearly 100% and ... serious illness but most men diagnosed with the disease do ...
(Date:7/31/2014)... its latest blog post, Best Drug Rehabilitation , which ... during a stay in rehab can make a big difference ... at 11 drug addiction facts that children aren’t taught in ... some kids learn a little about the dangers of alcohol ... woefully inadequate,” commented Best Drug Rehabilitation’s Per Wickstrom . ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Continuing ... the upcoming inaugural Clinical Issues in Primary Care ... October 13-17, 2014 at the Wailea Beach Marriott Resort ... agenda has been developed for today's Primary Care ... critical CME topics," says Barbara Lyons, VP Education. , ...
(Date:7/31/2014)... 31, 2014 Nuanced Media, a leading ... of the Nuanced Medical website . Nuanced Medical, ... needs of the Medical Industry. , The idea behind ... for medical practices to meet continuously changing federal regulations. ... HIPAA Act (Health Insurance Portability and Accountability Act), which ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The ... with the Penn's Abramson Cancer Center, will host a ... together area experts in the field of mesothelioma. September ... The conference is open to the public, and specifically ... and those who have been exposed to asbestos. , ...
Breaking Medicine News(10 mins):Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 2Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 3Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 4Health News:New Best Drug Rehabilitation Blog Posts Looks at 11 Drug Addiction Facts they Don’t Teach in School 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 3Health News:Nuanced Media, HIPAA Certified Agency, Launches Medical Web Design Service Website 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 3
... study in the Sept.1 issue of the journal ... workplace bullying is associated with increased sleep disturbances. Associations ... indicating that bullying has detrimental effects even when it ... high prevalence of workplace bullying, with 11 percent of ...
... More than 1,000 Reported Incidents, Caregivers Call for Comprehensive Process to ... Aug. 31 Home care workers called for a hand-examination ... the workers, union, saying they had been subjected to lies, coercion, ... members of the Service Employees International Union, United Healthcare Workers - ...
... Insurance company ... flight , ... August 31, 2009 -- Last year, Sally (a patient suffering from end stage liver failure) ... transplant. Her doctors told her she needed to receive the evaluation in order to get ...
... , , SAN FRANCISCO, ... full-service direct marketing agency staffed with seasoned marketing professionals and a ... appointed Robin Raff to the position of Director of Strategy for ... Raff reports directly to ECI CEO and President Bara Oscodar. ...
... , LAKE FOREST, Ill., Aug. 31 ... in generic injectable pharmaceuticals, today announced that the U.S. Food and ... presentations of therapeutic heparin in single- and multiple-dose vials. , ... central venous catheters and for anticoagulant (blood thinning) therapy, and is ...
... , , , SCOTTSDALE, Ariz., Aug. ... failure) was in need of life flight transportation ... needed to receive the evaluation in order to get on the transplant ... due to her condition. Her health insurance company told her they would ...
Cached Medicine News:Health News:Workplace bullying is associated with sleep disturbances 2Health News:Workplace bullying is associated with sleep disturbances 3Health News:San Francisco Home Care Workers Describe Lies, Coercion, and Fraud in Union Signature Drive 2Health News:San Francisco Home Care Workers Describe Lies, Coercion, and Fraud in Union Signature Drive 3Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 3Health News:ECI Hires Robin Raff as Director of Strategy 2Health News:Hospira Receives FDA Approval for Six New Presentations of Heparin 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 3
Semi-Automated Chemistry Analyzer with model screen master. The Screen Master incorporates many powerful features in one compact unit. Useful for biochemical investigations, enzymatic, immunoturbidi...
... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
... Unique molecular suspension in methanol for ... chromosome, and histology smears. Our special ... rapidly penetrates cellular elements producing unequaled ... detail and unexcelled brilliance in the ...
Wright-Giemsa Stain Solutions...
Medicine Products: